Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:DGX NASDAQ:EXAS NYSE:LH NASDAQ:NTRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDGXQuest Diagnostics$228.05+0.1%$203.23$165.78▼$237.78$25.22B0.581.01 million shs1.54 million shsEXASExact Sciences$104.91$103.67$38.81▼$104.98$20.03B1.413.55 million shsN/ALHLabcorp$296.71+2.0%$269.38$244.52▼$298.58$24.34B0.89679,521 shs916,277 shsNTRANatera$261.99-1.0%$240.75$131.81▼$288.04$37.52B1.511.28 million shs699,369 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDGXQuest Diagnostics0.00%+8.15%+10.53%+16.36%+33.93%EXASExact Sciences0.00%0.00%0.00%0.00%+116.71%LHLabcorp0.00%+4.61%+11.31%+12.46%+18.21%NTRANatera0.00%-3.46%+0.48%+28.58%+90.10%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDGXQuest Diagnostics$228.05+0.1%$203.23$165.78▼$237.78$25.22B0.581.01 million shs1.54 million shsEXASExact Sciences$104.91$103.67$38.81▼$104.98$20.03B1.413.55 million shsN/ALHLabcorp$296.71+2.0%$269.38$244.52▼$298.58$24.34B0.89679,521 shs916,277 shsNTRANatera$261.99-1.0%$240.75$131.81▼$288.04$37.52B1.511.28 million shs699,369 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDGXQuest Diagnostics0.00%+8.15%+10.53%+16.36%+33.93%EXASExact Sciences0.00%0.00%0.00%0.00%+116.71%LHLabcorp0.00%+4.61%+11.31%+12.46%+18.21%NTRANatera0.00%-3.46%+0.48%+28.58%+90.10%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDGXQuest Diagnostics 2.50Moderate Buy$231.731.61% UpsideEXASExact Sciences 1.95Reduce$92.13-12.19% DownsideLHLabcorp 2.80Moderate Buy$315.336.28% UpsideNTRANatera 2.82Moderate Buy$267.832.23% UpsideCurrent Analyst Ratings BreakdownLatest DGX, LH, EXAS, and NTRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/24/2026LHLabcorp Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)7/24/2026DGXQuest Diagnostics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$232.007/24/2026DGXQuest Diagnostics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$235.00 ➝ $260.007/24/2026DGXQuest Diagnostics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$225.00 ➝ $250.007/24/2026DGXQuest Diagnostics Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$236.00 ➝ $255.007/23/2026DGXQuest Diagnostics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$230.00 ➝ $250.007/23/2026DGXQuest Diagnostics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$245.007/17/2026NTRANatera Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/15/2026NTRANatera TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/14/2026NTRANatera Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell7/14/2026NTRANatera Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$285.00 ➝ $330.00(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDGXQuest Diagnostics$11.04B2.29$15.18 per share15.02$70.64 per share3.23EXASExact Sciences$3.25B6.17$1.27 per share82.83$12.58 per share8.34LHLabcorp$13.95B1.74$24.83 per share11.95$103.98 per share2.85NTRANatera$2.50B15.00N/AN/A$12.38 per share21.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDGXQuest Diagnostics$992M$9.4224.2119.382.619.18%16.01%7.27%N/AEXASExact Sciences-$207.95M-$1.10N/A209.822.02-6.40%0.53%0.22%N/ALHLabcorp$876.50M$11.2926.2815.351.976.66%16.29%7.62%7/30/2026 (Estimated)NTRANatera-$208.16M-$1.63N/AN/AN/A-9.05%-14.74%-10.27%8/6/2026 (Estimated)Latest DGX, LH, EXAS, and NTRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026NTRANatera-$0.4939N/AN/AN/A$661.24 millionN/A7/30/2026Q2 2026LHLabcorp$4.79N/AN/AN/A$3.71 billionN/A7/23/2026Q2 2026DGXQuest Diagnostics$2.82$3.12+$0.30$2.84$2.97 billion$3.04 billion4/30/2026Q1 2026LHLabcorp$4.09$4.25+$0.16$3.35$3.51 billion$3.54 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDGXQuest Diagnostics$3.441.51%+7.34%36.52%14 YearsEXASExact SciencesN/AN/AN/AN/AN/ALHLabcorp$2.880.97%N/A25.51%N/ANTRANateraN/AN/AN/AN/AN/ALatest DGX, LH, EXAS, and NTRA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/9/2026LHLabcorpquarterly$0.721.04%8/28/20268/28/20269/11/20265/19/2026DGXQuest Diagnosticsquarterly$0.861.65%7/8/20267/8/20267/22/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDGXQuest Diagnostics0.721.591.08EXASExact Sciences0.972.432.17LHLabcorp0.681.731.54NTRANateraN/A2.962.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDGXQuest Diagnostics88.06%EXASExact Sciences88.82%LHLabcorp95.94%NTRANatera99.90%Insider OwnershipCompanyInsider OwnershipDGXQuest Diagnostics0.88%EXASExact Sciences1.20%LHLabcorp0.84%NTRANatera5.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDGXQuest Diagnostics57,000110.70 million109.72 millionOptionableEXASExact Sciences7,200190.89 million188.60 millionOptionableLHLabcorp71,00082.00 million81.31 millionOptionableNTRANatera6,140143.22 million135.98 millionOptionableDGX, LH, EXAS, and NTRA HeadlinesRecent News About These CompaniesFirst Trust Advisors LP Acquires 209,056 Shares of Natera, Inc. $NTRAJuly 25 at 3:44 AM | marketbeat.comBeaconlight Capital LLC Raises Position in Natera, Inc. $NTRAJuly 25 at 3:21 AM | marketbeat.comNatera, Inc. $NTRA Shares Purchased by Arrowstreet Capital Limited PartnershipJuly 25 at 3:07 AM | marketbeat.comNatera’s New ctDNA-Guided Immunotherapy Trial Could Redefine Cancer Treatment CyclesJuly 24 at 12:51 PM | tipranks.comKBC Group NV Has $3.85 Million Position in Natera, Inc. $NTRAJuly 24 at 5:05 AM | marketbeat.comNatera, Inc. $NTRA Shares Sold by Hsbc Holdings PLCJuly 23 at 4:47 AM | marketbeat.comSwiss National Bank Increases Holdings in Natera, Inc. $NTRAJuly 22, 2026 | marketbeat.comNatera, Inc. $NTRA Shares Sold by California Public Employees Retirement SystemJuly 22, 2026 | marketbeat.comFifth Third Bancorp Acquires 10,929 Shares of Natera, Inc. $NTRAJuly 22, 2026 | marketbeat.comNatera, Inc. $NTRA Shares Purchased by Andra AP fondenJuly 22, 2026 | marketbeat.comSEB Asset Management AB Acquires Shares of 85,074 Natera, Inc. $NTRAJuly 21, 2026 | marketbeat.comJennison Associates LLC Grows Position in Natera, Inc. $NTRAJuly 21, 2026 | marketbeat.comAmova Asset Management Americas Inc. Has $84.69 Million Stake in Natera, Inc. $NTRAJuly 21, 2026 | marketbeat.comBillionaire Investor Stanley Druckenmiller's Top 5 Picks: Worth Buying Today?July 20, 2026 | 247wallst.comMeeder Asset Management Inc. Lowers Holdings in Natera, Inc. $NTRAJuly 20, 2026 | marketbeat.comNatera, Inc. $NTRA Shares Bought by Bank of New York Mellon CorpJuly 20, 2026 | marketbeat.comHanseatic Management Services Inc. Makes New $940,000 Investment in Natera, Inc. $NTRAJuly 19, 2026 | marketbeat.comPiper Sandler Sticks to Its Buy Rating for Natera (NTRA)July 18, 2026 | theglobeandmail.comAllspring Global Investments Holdings LLC Acquires 8,979 Shares of Natera, Inc. $NTRAJuly 18, 2026 | marketbeat.comJag Capital Management LLC Has $17.02 Million Stock Position in Natera, Inc. $NTRAJuly 17, 2026 | marketbeat.comPrincipal Financial Group Inc. Sells 8,430 Shares of Natera, Inc. $NTRAJuly 17, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 2026These 3 Stocks Offer Investors Exposure to the Functional Beverage BoomBy Chris Markoch | July 6, 2026CleanSpark Inks a $6.6B AI Lease to Become a Digital LandlordBy Jeffrey Neal Johnson | July 15, 2026A Boring Dividend Growth Strategy Becomes a Solid Defensive PlayBy Nathan Reiff | July 22, 2026Texas Power Play: Hut 8 Sparks a $9.8B AI Infrastructure DealBy Jeffrey Neal Johnson | July 22, 2026DGX, LH, EXAS, and NTRA Company DescriptionsQuest Diagnostics NYSE:DGX$228.05 +0.15 (+0.07%) Closing price 07/24/2026 03:59 PM EasternExtended Trading$232.01 +3.96 (+1.74%) As of 07/24/2026 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.Exact Sciences NASDAQ:EXASExact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Labcorp NYSE:LH$296.71 +5.69 (+1.96%) Closing price 07/24/2026 03:59 PM EasternExtended Trading$296.82 +0.11 (+0.04%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.Natera NASDAQ:NTRA$261.99 -2.70 (-1.02%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$261.86 -0.13 (-0.05%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
